Added value of whole-genome sequencing for management of highly drug-resistant TB.

ABSTRACT:

Objectives

Phenotypic drug susceptibility testing (DST) for Mycobacterium tuberculosis takes several weeks to complete and second-line DST is often poorly reproducible, potentially leading to compromised clinical decisions. Following a fatal case of XDR TB, we investigated the potential benefit of using whole-genome sequencing to generate an in silico drug susceptibility profile.

Methods

The clinical course of the patient was reviewed, assessing the times at which phenotypic DST data became available and changes made to the therapeutic regimen. Whole-genome sequencing was performed on the earliest available isolate and variants associated with drug resistance were identified.

Results

The final DST report, including second-line drugs, was issued 10 weeks after patient

SUBMITTER: Outhred AC 

PROVIDER: S-EPMC4356205 | biostudies-literature | 2015 Apr

REPOSITORIES: biostudies-literature